Tumors of the Anterior Prostate: Implications for Diagnosis and Treatment.

Tumors of the anterior prostate (ie, the portion of the prostate anterior to the urethra) account for approximately 20% of all prostate cancers. Although anterior prostate cancers frequently occur, they have historically been underdetected because of infrequent sampling. Recent advances in multiparametric magnetic resonance imaging and improved biopsy schemes have significantly increased our diagnostic accuracy for detecting anterior tumors.

Accuracy and implications of percutaneous renal biopsy in the management of renal masses.

Introduction: Percutaneous renal biopsy in patients with renal masses is increasing. We investigated the accuracy of percutaneous renal mass biopsy results in patients undergoing evaluation of solid renal masses.

Methods: A retrospective review was performed of patients in the Kaiser Permanente Southern California Region who underwent computed tomography or ultrasound-guided percutaneous renal biopsy of a solid renal mass between January 2005 and December 2009.

Ex vivo lymphatic mapping: a technique to improve pathologic staging in colorectal cancer.

Sentinel lymph node (SLN) biopsy is widely used for solid tumors and has been proposed for use in staging colorectal cancer (CRC). Few studies have examined the ex vivo lymphatic mapping (EVLM) technique for staging CRC. We hypothesized that EVLM is technically feasible, sensitive, accurate, and improves the staging of CRC.

Does tumor burden limit the accuracy of lymphatic mapping and sentinel lymph node biopsy in colorectal cancer?

Purpose: Sentinel lymph node (SLN) biopsy is a widely accepted method for staging breast cancer and melanoma, and it has recently been proposed as a means of improving staging in colorectal cancer. However, lymphatic mapping in colorectal cancer has been plagued by studies demonstrating high false-negative rates. The purpose of this study was to evaluate possible mechanisms for high false-negative rates after SLN biopsy in colorectal cancer.